Abiri Onome T, Ninka Alex, Coker Joshua, Thomas Fawzi, Smalle Isaac O, Lakoh Sulaiman, Turay Foday Umaro, Komeh James, Sesay Mohamed, Kanu Joseph Sam, Mustapha Ayeshatu M, Bell Nellie V T, Conteh Thomas Ansumus, Conteh Sarah Kadijatu, Jalloh Alhaji Alusine, Russell James B W, Sesay Noah, Bawoh Mohamed, Samai Mohamed, Lahai Michael
Department of Pharmacology and Therapeutics, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.
Department of Pharmacovigilance and Clinical Trials, Pharmacy Board of Sierra Leone, Freetown, Sierra Leone.
Pediatric Health Med Ther. 2024 Mar 29;15:145-158. doi: 10.2147/PHMT.S451453. eCollection 2024.
Pediatric patients are prone to medicine-related problems like medication errors (MEs), which can potentially cause harm. Yet, this has not been studied in this population in Sierra Leone. Therefore, this study investigated the prevalence and nature of MEs, including potential drug-drug interactions (pDDIs), in pediatric patients.
The study was conducted in three hospitals among pediatric patients in Freetown and consisted of two phases. Phase one was a cross-sectional retrospective review of prescriptions for completeness and accuracy based on the global accuracy score against standard prescription writing guidelines. Phase two was a point prevalence inpatient chart review of MEs categorized into prescription, administration, and dispensing errors and pDDIs. Data was analyzed using frequency, percentages, median, and interquartile range. Kruskal-Wallis H and Mann-Whitney -tests were used to compare the prescription accuracy between the hospitals, with p<0.05 considered statistically significant.
Three hundred and sixty-six (366) pediatric prescriptions and 132 inpatient charts were reviewed in phases one and two of the study, respectively. In phase one, while no prescription attained the global accuracy score (GAS) gold standard of 100%, 106 (29.0%) achieved the 80-100% mark. The patient 63 (17.2%), treatment 228 (62.3%), and prescriber 33 (9.0%) identifiers achieved an overall GAS range of 80-100%. Although the total GAS was not statistically significant (p=0.065), the date (p=0.041), patient (p=<0.001), treatment (p=0.022), and prescriber (p=<0.001) identifiers were statistically significant across the different hospitals. For phase two, the prevalence of MEs was 74 (56.1%), while that of pDDIs was 54 (40.9%). There was a statistically positive correlation between the occurrence of pDDI and number of medicines prescribed (r=0.211, P=0.015).
A Low GAS indicates poor compliance with prescription writing guidelines and high prescription errors. Medication errors were observed at each phase of the medication use cycle, while clinically significant pDDIs were also reported. Thus, there is a need for training on prescription writing guidelines and medication errors.
儿科患者容易出现与药物相关的问题,如用药错误(MEs),这可能会造成伤害。然而,在塞拉利昂的这一人群中尚未对此进行研究。因此,本研究调查了儿科患者中用药错误的发生率和性质,包括潜在药物相互作用(pDDIs)。
该研究在弗里敦的三家医院对儿科患者进行,包括两个阶段。第一阶段是根据全球准确性评分对照标准处方书写指南对处方的完整性和准确性进行横断面回顾性审查。第二阶段是对用药错误进行点患病率住院病历审查,用药错误分为处方、给药和调配错误以及潜在药物相互作用。使用频率、百分比、中位数和四分位间距对数据进行分析。采用Kruskal-Wallis H检验和Mann-Whitney检验比较各医院之间的处方准确性,p<0.05被认为具有统计学意义。
在研究的第一阶段和第二阶段,分别审查了366份儿科处方和132份住院病历。在第一阶段,虽然没有处方达到100%的全球准确性评分(GAS)金标准,但106份(29.0%)达到了80-100%的分数。患者标识符63份(17.2%)、治疗标识符228份(62.3%)和开处方者标识符33份(9.0%)的总体GAS范围为80-100%。虽然总GAS无统计学意义(p=0.065),但日期(p=0.041)、患者(p<0.001)、治疗(p=0.022)和开处方者(p<0.001)标识符在不同医院之间具有统计学意义。在第二阶段,用药错误的发生率为74例(56.1%),而潜在药物相互作用的发生率为54例(40.9%)。潜在药物相互作用的发生与所开药物数量之间存在统计学上的正相关(r=0.211,P=0.015)。
低GAS表明对处方书写指南的依从性差且处方错误率高。在药物使用周期的每个阶段都观察到了用药错误,同时也报告了具有临床意义的潜在药物相互作用。因此,需要对处方书写指南和用药错误进行培训。